Iradimed Corp. (IRMD) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Iradimed’s revenue went from $32M in fiscal 2016 to $84M in fiscal 2025, growth of about 11.1% a year.
Net income in fiscal 2025 was $22M, a net margin of 26.8%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $89M and net income $24M.
Free cash flow was $17M in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count rose 7% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $89M | $84M | $73M | $66M | $53M | $42M | $32M | $39M | $30M | $23M | $32M |
| Gross profit | $67M | $64M | $56M | $50M | $41M | $32M | $24M | $30M | $23M | $18M | $26M |
| Operating income | $29M | $26M | $22M | $20M | $16M | $10M | -$756091 | $9M | $6M | $1M | $11M |
| Net income | $24M | $22M | $19M | $17M | $13M | $9M | $1M | $10M | $6M | $499764 | $7M |
| EPS (diluted) | $1.87 | $1.75 | $1.50 | $1.35 | $1.02 | $0.74 | $0.11 | $0.78 | $0.52 | $0.04 | $0.60 |
| R&D | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $1M | $2M | $2M | $1M |
| Revenue growth | — | +14.4% | +11.7% | +23.0% | +27.5% | +31.8% | −17.6% | +26.5% | +31.9% | −29.0% | +2.9% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $27M | $25M | $26M | $13M | $10M | $11M | $6M | $10M | $7M | $3M | $9M |
| Capital spending | -$1M | -$8M | -$8M | -$7M | -$823019 | -$482325 | -$443003 | -$368281 | -$228315 | -$775574 | -$780809 |
| Free cash flow | $26M | $17M | $18M | $6M | $9M | $11M | $5M | $10M | $7M | $3M | $9M |
| Dividends paid | $16M | $15M | $14M | $13M | $13M | — | — | — | — | — | — |
| Buybacks | — | — | — | — | — | — | — | — | — | $2M | $10M |
| Stock-based pay | $3M | $3M | $3M | $2M | $1M | $1M | $4M | $2M | $2M | $2M | $2M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $51M | $52M | $50M | $58M | $63M | $52M | $46M | $34M | $26M | $18M |
| Debt | — | $0 | $154688 | $2M | $3M | $2M | $3M | $3M | $0 | $0 | $0 |
| Equity | — | $95M | $87M | $71M | $74M | $72M | $61M | $56M | $42M | $33M | $32M |
| Total assets | — | $109M | $98M | $92M | $86M | $83M | $71M | $67M | $48M | $39M | $37M |
| Shares (diluted) | 13M | 13M | 13M | 13M | 13M | 13M | 12M | 12M | 12M | 12M | 12M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 75.5% | 76.8% | 76.9% | 76.5% | 77.5% | 76.6% | 74.3% | 77.1% | 76.3% | 75.9% | 81.1% |
| Operating margin | 32.3% | 31.2% | 30.0% | 30.6% | 29.3% | 23.5% | -2.4% | 22.4% | 19.7% | 5.6% | 33.6% |
| Net margin | 26.8% | 26.8% | 26.3% | 26.2% | 24.1% | 22.3% | 4.3% | 25.0% | 20.7% | 2.2% | 22.2% |
| FCF margin | 29.3% | 20.5% | 24.1% | 9.2% | 17.3% | 25.8% | 16.9% | 25.6% | 23.5% | 11.4% | 26.5% |
| ROIC | — | 21.9% | 20.0% | 21.6% | 16.2% | 12.5% | -0.9% | 11.7% | 11.3% | 3.1% | 22.6% |
| ROE | — | 23.8% | 22.1% | 24.1% | 17.4% | 12.9% | 2.2% | 17.3% | 15.0% | 1.5% | 22.6% |
Frequently asked questions
What is Iradimed’s annual revenue?
$84M in fiscal 2025 and $89M over the twelve months to September 30, 2026.
How much profit does Iradimed make?
Net income was $22M in fiscal 2025 (net margin 26.8%).
Is Iradimed’s revenue growing?
Yes: revenue rose 14.4% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.